BTRX-335140

BTRX-335140

Clinical data
Other names	BTRX-140; CYM-53093; NMRA-140
Identifiers
IUPAC name 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
CAS Number	2244614-14-8
PubChem CID	137434175
ChemSpider	78316413
UNII	XK5ILZ28KI
Chemical and physical data
Formula	C25H32FN5O2
Molar mass	453.562 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
InChI InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3 Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N

BTRX-335140, also known by its other developmental code names BTRX-140, CYM-53093, and NMRA-140, is an opioid antagonist medication which is under development for the treatment of depression. It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder. As of February 2020, BTRX-335140 is in phase 2 clinical trials for this indication.

See also

• κ-Opioid receptor § Antagonists
• List of investigational antidepressants

External links

• BTRX 335140 - AdisInsight